DOI: 10.1055/s-00000077

Seminars in Thrombosis and Hemostasis

Issue 03 · Volume 43 · April 2017 DOI: 10.1055/s-007-33727 Laboratory Assessment of Hemostatic and Anticoagulant Therapy Guest Editors: Robert C. Gosselin, CLS, and Dorothy M. Adcock, MD.

Editorial

235
Favaloro, Emmanuel J.: 2016 Eberhard F. Mammen Award Announcements: Part II—Young Investigator Awards

Preface

242
Adcock, Dorothy M.; Gosselin, Robert C.: Laboratory Assessment of Hemostatic and Anticoagulant Therapy

Original Article

245
Moffat, Karen A.; Lewis, Clinton W.: Laboratory Monitoring of Oral Vitamin K Anticoagulation

Review Article

253
Marlar, Richard A.; Clement, Bernadette; Gausman, Jana: Activated Partial Thromboplastin Time Monitoring of Unfractionated Heparin Therapy: Issues and Recommendations
261
Babin, Jennifer L.; Traylor, Katie L.; Witt, Daniel M.: Laboratory Monitoring of Low-Molecular-Weight Heparin and Fondaparinux
270
Van Cott, Elizabeth M.; Roberts, A. Joshua; Dager, William E.: Laboratory Monitoring of Parenteral Direct Thrombin Inhibitors
277
Douxfils, Jonathan; Gosselin, Robert C.: Laboratory Assessment of Direct Oral Anticoagulants
291
Winkler, Anne M.: Managing the Precarious Hemostatic Balance during Extracorporeal Life Support: Implications for Coagulation Laboratories
300
Kluft, Cornelis; Sidelmann, Johannes J.; Gram, Jørgen B.: Assessing Safety of Thrombolytic Therapy
311
Orme, Rachel; Judge, Heather M.; Storey, Robert F.: Monitoring Antiplatelet Therapy
320
Castellone, Donna D.; Adcock, Dorothy M.: Factor VIII Activity and Inhibitor Assays in the Diagnosis and Treatment of Hemophilia A
331
Kitchen, Steve; Tiefenbacher, Stefan; Gosselin, Robert: Factor Activity Assays for Monitoring Extended Half-Life FVIII and Factor IX Replacement Therapies
338
Favaloro, Emmanuel J.; Pasalic, Leonardo; Curnow, Jennifer: Monitoring Therapy during Treatment of von Willebrand Disease

Letter to the Editor

355
Kubisz, Peter; Stasko, Jan; Holly, Pavol: Use of Low-Dose Recombinant Activated Factor VII in the Off-Label Setting: A Comment to “The Judicious Use of Recombinant Factor VIIa”